MECHANISMS OF HISTAMINE RELEASE FROM MAST CELLS BEYOND THE HIGH AFFINITY IgE RECEPTOR IN SEVERE CHRONIC SPONTANEOUS URTICARIA
Immunol Lett. 2023 Nov 30:S0165-2478(23)00195-5. doi: 10.1016/j.imlet.2023.11.008. Online ahead of print.ABSTRACTThere is growing evidence suggesting that in a subset of patients with severe chronic urticaria (CSU) mast cells are activated via mechanisms that bypass the high affinity IgE receptor. This might explain why some patients do not respond at all to anti-IgE therapy (omalizumab). The present article reviews the pathogenic mechanisms able to lead to histamine release from mast cells described so far in patients with CSU. These include the activation of the coagulation cascade, the activation of the complement syste...
Source: Immunology Letters - December 2, 2023 Category: Allergy & Immunology Authors: Riccardo Asero Source Type: research
Mechanisms of histamine release from mast cells beyond the high affinity IgE receptor in severe chronic spontaneous urticaria
Immunol Lett. 2023 Nov 30;265:1-4. doi: 10.1016/j.imlet.2023.11.008. Online ahead of print.ABSTRACTThere is growing evidence suggesting that in a subset of patients with severe chronic urticaria [CSU] mast cells are activated via mechanisms that bypass the high affinity IgE receptor. This might explain why some patients do not respond at all to anti-IgE therapy [omalizumab]. The present article reviews the pathogenic mechanisms able to lead to histamine release from mast cells described so far in patients with CSU. These include the activation of the coagulation cascade, the activation of the complement system, the activat...
Source: Immunology Letters - December 2, 2023 Category: Allergy & Immunology Authors: Riccardo Asero Source Type: research
Mechanisms of histamine release from mast cells beyond the high affinity IgE receptor in severe chronic spontaneous urticaria
Immunol Lett. 2023 Nov 30;265:1-4. doi: 10.1016/j.imlet.2023.11.008. Online ahead of print.ABSTRACTThere is growing evidence suggesting that in a subset of patients with severe chronic urticaria [CSU] mast cells are activated via mechanisms that bypass the high affinity IgE receptor. This might explain why some patients do not respond at all to anti-IgE therapy [omalizumab]. The present article reviews the pathogenic mechanisms able to lead to histamine release from mast cells described so far in patients with CSU. These include the activation of the coagulation cascade, the activation of the complement system, the activat...
Source: Immunology Letters - December 2, 2023 Category: Allergy & Immunology Authors: Riccardo Asero Source Type: research
Mechanisms of histamine release from mast cells beyond the high affinity IgE receptor in severe chronic spontaneous urticaria
Immunol Lett. 2023 Nov 30;265:1-4. doi: 10.1016/j.imlet.2023.11.008. Online ahead of print.ABSTRACTThere is growing evidence suggesting that in a subset of patients with severe chronic urticaria [CSU] mast cells are activated via mechanisms that bypass the high affinity IgE receptor. This might explain why some patients do not respond at all to anti-IgE therapy [omalizumab]. The present article reviews the pathogenic mechanisms able to lead to histamine release from mast cells described so far in patients with CSU. These include the activation of the coagulation cascade, the activation of the complement system, the activat...
Source: Immunology Letters - December 2, 2023 Category: Allergy & Immunology Authors: Riccardo Asero Source Type: research
Mechanisms of histamine release from mast cells beyond the high affinity IgE receptor in severe chronic spontaneous urticaria
Immunol Lett. 2023 Nov 30;265:1-4. doi: 10.1016/j.imlet.2023.11.008. Online ahead of print.ABSTRACTThere is growing evidence suggesting that in a subset of patients with severe chronic urticaria [CSU] mast cells are activated via mechanisms that bypass the high affinity IgE receptor. This might explain why some patients do not respond at all to anti-IgE therapy [omalizumab]. The present article reviews the pathogenic mechanisms able to lead to histamine release from mast cells described so far in patients with CSU. These include the activation of the coagulation cascade, the activation of the complement system, the activat...
Source: Immunology Letters - December 2, 2023 Category: Allergy & Immunology Authors: Riccardo Asero Source Type: research
Mechanisms of histamine release from mast cells beyond the high affinity IgE receptor in severe chronic spontaneous urticaria
Immunol Lett. 2023 Nov 30;265:1-4. doi: 10.1016/j.imlet.2023.11.008. Online ahead of print.ABSTRACTThere is growing evidence suggesting that in a subset of patients with severe chronic urticaria [CSU] mast cells are activated via mechanisms that bypass the high affinity IgE receptor. This might explain why some patients do not respond at all to anti-IgE therapy [omalizumab]. The present article reviews the pathogenic mechanisms able to lead to histamine release from mast cells described so far in patients with CSU. These include the activation of the coagulation cascade, the activation of the complement system, the activat...
Source: Immunology Letters - December 2, 2023 Category: Allergy & Immunology Authors: Riccardo Asero Source Type: research
Mechanisms of histamine release from mast cells beyond the high affinity IgE receptor in severe chronic spontaneous urticaria
Immunol Lett. 2023 Nov 30;265:1-4. doi: 10.1016/j.imlet.2023.11.008. Online ahead of print.ABSTRACTThere is growing evidence suggesting that in a subset of patients with severe chronic urticaria [CSU] mast cells are activated via mechanisms that bypass the high affinity IgE receptor. This might explain why some patients do not respond at all to anti-IgE therapy [omalizumab]. The present article reviews the pathogenic mechanisms able to lead to histamine release from mast cells described so far in patients with CSU. These include the activation of the coagulation cascade, the activation of the complement system, the activat...
Source: Immunology Letters - December 2, 2023 Category: Allergy & Immunology Authors: Riccardo Asero Source Type: research
Mechanisms of histamine release from mast cells beyond the high affinity IgE receptor in severe chronic spontaneous urticaria
Immunol Lett. 2023 Nov 30;265:1-4. doi: 10.1016/j.imlet.2023.11.008. Online ahead of print.ABSTRACTThere is growing evidence suggesting that in a subset of patients with severe chronic urticaria [CSU] mast cells are activated via mechanisms that bypass the high affinity IgE receptor. This might explain why some patients do not respond at all to anti-IgE therapy [omalizumab]. The present article reviews the pathogenic mechanisms able to lead to histamine release from mast cells described so far in patients with CSU. These include the activation of the coagulation cascade, the activation of the complement system, the activat...
Source: Immunology Letters - December 2, 2023 Category: Allergy & Immunology Authors: Riccardo Asero Source Type: research
Mechanisms of histamine release from mast cells beyond the high affinity IgE receptor in severe chronic spontaneous urticaria
Immunol Lett. 2023 Nov 30;265:1-4. doi: 10.1016/j.imlet.2023.11.008. Online ahead of print.ABSTRACTThere is growing evidence suggesting that in a subset of patients with severe chronic urticaria [CSU] mast cells are activated via mechanisms that bypass the high affinity IgE receptor. This might explain why some patients do not respond at all to anti-IgE therapy [omalizumab]. The present article reviews the pathogenic mechanisms able to lead to histamine release from mast cells described so far in patients with CSU. These include the activation of the coagulation cascade, the activation of the complement system, the activat...
Source: Immunology Letters - December 2, 2023 Category: Allergy & Immunology Authors: Riccardo Asero Source Type: research
Mechanisms of histamine release from mast cells beyond the high affinity IgE receptor in severe chronic spontaneous urticaria
Immunol Lett. 2023 Nov 30;265:1-4. doi: 10.1016/j.imlet.2023.11.008. Online ahead of print.ABSTRACTThere is growing evidence suggesting that in a subset of patients with severe chronic urticaria [CSU] mast cells are activated via mechanisms that bypass the high affinity IgE receptor. This might explain why some patients do not respond at all to anti-IgE therapy [omalizumab]. The present article reviews the pathogenic mechanisms able to lead to histamine release from mast cells described so far in patients with CSU. These include the activation of the coagulation cascade, the activation of the complement system, the activat...
Source: Immunology Letters - December 2, 2023 Category: Allergy & Immunology Authors: Riccardo Asero Source Type: research
Mechanisms of histamine release from mast cells beyond the high affinity IgE receptor in severe chronic spontaneous urticaria
Immunol Lett. 2023 Nov 30;265:1-4. doi: 10.1016/j.imlet.2023.11.008. Online ahead of print.ABSTRACTThere is growing evidence suggesting that in a subset of patients with severe chronic urticaria [CSU] mast cells are activated via mechanisms that bypass the high affinity IgE receptor. This might explain why some patients do not respond at all to anti-IgE therapy [omalizumab]. The present article reviews the pathogenic mechanisms able to lead to histamine release from mast cells described so far in patients with CSU. These include the activation of the coagulation cascade, the activation of the complement system, the activat...
Source: Immunology Letters - December 2, 2023 Category: Allergy & Immunology Authors: Riccardo Asero Source Type: research
Cost-effectiveness analysis of dupilumab versus omalizumab, mepolizumab and benralizumab added to the standard of care in adults with severe asthma in Colombia
CONCLUSIONS: Dupilumab 200 mg was strongly dominant versus omalizumab 450 mg and600 mg, mepolizumab 100 mg and benralizumab 30 mg; however,cost-effectiveness was not demonstrated versus omalizumab 300 mg.These findings might aid in the selection of a biologic to treatsevere type 2 asthma.PMID:37994432 | DOI:10.1080/14737167.2023.2282668 (Source: Expert Review of Pharmacoeconomics and Outcomes Research)
Source: Expert Review of Pharmacoeconomics and Outcomes Research - November 23, 2023 Category: Health Management Authors: Abraham Ali Elizabeth Garc ía Carlos A Torres-Duque Diana Rey Laura Botero Stid Saenz Maria Paula Avila Elizabeth Mazo Sergio Londo ño Source Type: research
Rituximab and Omalizumab Combination Therapy for Bullous Pemphigoid
This research letter reports on a case series of 10 patients with bullous pemphigoid treated with rituximab combined with omalizumab. (Source: JAMA Dermatology)
Source: JAMA Dermatology - November 22, 2023 Category: Dermatology Source Type: research
Type 2 Biomarkers for the Indication and Response to Biologics in CRSwNP
AbstractPurpose of ReviewThree biologics targeting type 2 inflammation have been approved for the treatment of severe and uncontrolled chronic rhinosinusitis with nasal polyps (CRSwNP). Nevertheless, around 40 –60% of patients do not respond well to these biological treatments. Selecting appropriate patients is crucial to improve treatment outcome of biologics. This review summarizes the literature data on type 2 biomarkers, with a specific focus on the indication to biologics for severe CRSwNP.Recent FindingsNo consensus has been reached on how to define mucosal type 2 inflammation in CRSwNP. Clinical markers (e.g., 22-...
Source: Current Allergy and Asthma Reports - November 21, 2023 Category: Allergy & Immunology Source Type: research
Combined analytical assays for the characterization of drugs binding to human IgE: Applicability to omalizumab-bearing biosimilar candidates assessment
Biomed Pharmacother. 2023 Nov 14;169:115848. doi: 10.1016/j.biopha.2023.115848. Online ahead of print.ABSTRACTAnalytical and functional comparison is key for substantiating the level of convergence (essential sameness) or divergence between versions or variants of a given biological medicine. Accordingly, an overlapping biological activity between products meant to be equal probably reflects a highly similar structure and anticipates a comparable pharmacodynamic behavior. We developed an orthogonal approach to compare the human IgE binding features of different lots and versions of Xolair® (omalizumab), an anti-human IgE ...
Source: Biomedicine and pharmacotherapy = Biomedecine and pharmacotherapie - November 17, 2023 Category: Drugs & Pharmacology Authors: Adri án Urbano Judith Plaza C ésar Picado Fernando de Mora Source Type: research
